⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYTX News
Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
globenewswire.com
KYTX
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
globenewswire.com
KYTX
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
globenewswire.com
KYTX
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
globenewswire.com
KYTX
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com
KYTX
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
globenewswire.com
KYTX
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
globenewswire.com
KYTX
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
globenewswire.com
KYTX
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
globenewswire.com
KYTX
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
globenewswire.com
KYTX